Erythropoietin, known as recombinant human erythropoietin injection, does not usually cause an increase in creatinine.
Recombinant human erythropoietin injection can be used for anemia due to renal insufficiency, including chronic renal failure on dialysis and non-dialysis treatment. It is not indicated for the treatment of anemia caused by chemotherapy applied to non-myeloid malignancies, and is not indicated for the treatment of anemia caused by other factors in oncology patients.
Kidney has endocrine function and can secrete erythropoietin, which can promote bone marrow hematopoiesis after entering the body. Elevated creatinine is mainly caused by decreased glomerular filtration rate function. The use of recombinant human erythropoietin injection does not reduce the function of glomerular filtration rate, so it generally does not cause creatinine elevation.
Adverse reactions such as headache, low-grade fever, malaise, muscle pain, rash, elevated blood pressure, nausea and vomiting may occur after the use of Recombinant Human Erythropoietin Injection.
Patients with uncontrolled severe hypertension, those who are allergic to this product and other mammalian cell derivatives, and those who are allergic to human serum albumin need to be contraindicated. For those with co-infections, it is advisable to control the infection before using the product.
Patients are advised to use Recombinant Human Erythropoietin Injection under the supervision of a doctor and not to use it privately.